The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

C2i Genomics, Riken Genesis to expand AI-powered whole-genome MRD cancer detection technology across Japan

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

C2i Genomics entered a collaboration agreement March 2 with Riken Genesis Co., Ltd. to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 
By Ghulam Rasool, Brian D. Gonzalez and Katherine Chung-Bridges
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account